WO2004032957A1 - Immunization of non-human mammals against streptococcus equi - Google Patents
Immunization of non-human mammals against streptococcus equi Download PDFInfo
- Publication number
- WO2004032957A1 WO2004032957A1 PCT/SE2003/001587 SE0301587W WO2004032957A1 WO 2004032957 A1 WO2004032957 A1 WO 2004032957A1 SE 0301587 W SE0301587 W SE 0301587W WO 2004032957 A1 WO2004032957 A1 WO 2004032957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- equi
- antigenic
- seq
- vaccine
- Prior art date
Links
- 241000194048 Streptococcus equi Species 0.000 title claims abstract description 55
- 230000003053 immunization Effects 0.000 title claims abstract description 38
- 238000002649 immunization Methods 0.000 title abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 119
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 94
- 239000000427 antigen Substances 0.000 claims abstract description 55
- 102000036639 antigens Human genes 0.000 claims abstract description 54
- 108091007433 antigens Proteins 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 230000000890 antigenic effect Effects 0.000 claims abstract description 46
- 229960005486 vaccine Drugs 0.000 claims abstract description 42
- 241001339231 Streptococcus equi subsp. equi Species 0.000 claims abstract description 22
- 241000283086 Equidae Species 0.000 claims description 46
- 241001465754 Metazoa Species 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 208000015181 infectious disease Diseases 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 21
- 239000002671 adjuvant Substances 0.000 claims description 19
- 241000283073 Equus caballus Species 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 102000008186 Collagen Human genes 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 claims description 16
- 229920001436 collagen Polymers 0.000 claims description 16
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 claims description 5
- 102000036072 fibronectin binding proteins Human genes 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 230000005875 antibody response Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 210000004898 n-terminal fragment Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 83
- 241000699670 Mus sp. Species 0.000 description 59
- 150000001413 amino acids Chemical group 0.000 description 34
- 101000854604 Mus musculus Protein FAM167B Proteins 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 102100022810 Potassium voltage-gated channel subfamily H member 1 Human genes 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 238000005406 washing Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102100027287 Serpin H1 Human genes 0.000 description 7
- 108050008290 Serpin H1 Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 241000193996 Streptococcus pyogenes Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000304 virulence factor Substances 0.000 description 5
- 230000007923 virulence factor Effects 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101100477658 Drosophila melanogaster SclB gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000011544 gradient gel Substances 0.000 description 3
- 229940042743 immune sera Drugs 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 102100032965 Myomesin-2 Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000017730 intein-mediated protein splicing Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- COAABSMONFNYQH-TTWCUHKNSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-(oxiran-2-ylmethylsulfanyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1SCC1OC1 COAABSMONFNYQH-TTWCUHKNSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 101000743092 Bacillus spizizenii (strain DSM 15029 / JCM 12233 / NBRC 101239 / NRRL B-23049 / TU-B-10) tRNA3(Ser)-specific nuclease WapA Proteins 0.000 description 1
- 101000743093 Bacillus subtilis subsp. natto (strain BEST195) tRNA(Glu)-specific nuclease WapA Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010059574 C5a peptidase Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000016550 Complement Factor H Human genes 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 101710161637 DNA-entry nuclease Proteins 0.000 description 1
- 101710188144 Eag protein Proteins 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241001670226 Equus caballus x asinus Species 0.000 description 1
- 101000759374 Escherichia phage P2 Tail sheath protein Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 101710128530 Fibrinogen-binding protein Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000176030 Nanna Species 0.000 description 1
- 206010028720 Nasal abscess Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 101710137510 Saimiri transformation-associated protein Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001367772 Streptococcus pyogenes JRS4 Species 0.000 description 1
- 101100369116 Streptococcus pyogenes serotype M6 (strain ATCC BAA-946 / MGAS10394) tee6 gene Proteins 0.000 description 1
- 241001468181 Streptococcus sp. 'group C' Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 101710116805 Trypsin-resistant surface T6 protein Proteins 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 102000033737 extracellular matrix binding proteins Human genes 0.000 description 1
- 108091009712 extracellular matrix binding proteins Proteins 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 102000025748 fibrinogen binding proteins Human genes 0.000 description 1
- 108091010988 fibronectin binding proteins Proteins 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108010010318 streptococcal M protein Proteins 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000007078 todd-hewitt medium Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention is generally related to antigenic compositions and use thereof for immunization of non-human mammals, e.g. horses, against Streptococcus equi.
- Streptococcal infections in horses are mainly caused by the species Streptococcus equi, which is classified as a Lancefield Group C Streptococcus and comprises two subspecies designated equi and zooepidemicus, respectively.
- Streptococcus equi subsp. equi which is virtually confined to horses, is the causative agent of strangles, a world- wide distributed and highly contagious serious disease of the upper respiratory tract of the Equidae. Strangles is one of the most frequently reported equine diseases world-wide and is characterized by fever, nasal discharge, and abscess formation in the retropharyngeal and mandibular lymph nodes. In some cases the disease shows a metastatic course in the body, so called "bastard strangles". The disease has a world-wide distribution and causes great economic losses. Moreover, since strangles is a highly contagious disease, not only infected animals but also all other members of e.g. an afflicted stud must be isolated for as long as up to three months.
- S equi subsp. zooepidemicus is considered as an opportunistic commensal often occurring in the upper respiratory tract of healthy horses. However, after stress or virus infection, it can cause a secondary infection, which results in strangles-like symptoms. Moreover, subsp. zooepidemicus infects not only horses but also a wide range of other animals, like pigs, dogs, cats, and cows. Even human cases of infection due to subsp. zooepidemicus have been reported. This subspecies has been implicated as the primary pathogen in conditions such as endometritis, cervicitis, abortion, mastitis, pneumonia, abscesses and joint infections.
- Fibronectin is a dimeric glycoprotein found both in plasma and in a fibrillar form in the extracellular matrix.
- the main function of Fn is to mediate substrate adhesion of eukaryotic cells, which involves the binding of specific cell-surface receptors to certain domains of the Fn molecule. Furthermore, it also interacts with several other macromolecules, such as DNA, heparin, fibrin, and collagen.
- Fn-binding proteins from different streptococcal species have been cloned and sequenced previously.
- one Fn-binding protein has been cloned and characterized, which is a Fn-binding cell-surface protein of subsp. zooepidemicus, that has been designated FNZ (Lindmark et al., 1996, Ref. 9).
- Another Fn-binding protein from S equi subsp. equi has been cloned and characterized by Lindmark and Guss (1999) (Ref. 12). This latter protein that is designated SFS and its potential use as an active component in a vaccine for protection of horses against strangles are disclosed in WO 00/37496.
- ZAG a protein designated ZAG has been cloned and characterized from S. equi subsp. zooepidemicus that mediates binding to the plasma proteinase inhibitor ⁇ 2 M. It is speculated therein that this protein is similar in function to streptococcal M proteins.
- This protein, ZAG is also disclosed in WO 95/07296, where its ⁇ M-binding properties are indicated. However, immunogenic properties or potential use thereof as an active component in a vaccine for protection of e.g. horses against strangles are not disclosed therein.
- the gene zag encoding ZAG is also disclosed in these references.
- a gene that is similar to the aforesaid zag gene from S. equi subsp. zooepidemicus but is present in subsp. equi has been described by Lindmark et al. (1999) (Ref. 11) and Lindmark (1999) (Ref .13). This gene is hereafter designated eag and encodes a protein designated EAG.
- the present invention is based on an antigenic composition
- an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against S. equi subsp. equi and/or subsp. zooepidemicus.
- the present invention is also directed to a vaccine composition
- a vaccine composition comprising the afore- said antigenic composition as immunizing component, methods to prepare said antigenic or vaccine composition, methods to induce an immune response against S. equi in non-human mammals and methods for prophylactic or therapeutic treatment of S. equi infection in non- human mammals.
- S. equi refers to one or both of subsp. equi and subsp. zooepidemicus.
- the present invention is directed to a vaccine that protects equines, such as horses, against strangles.
- non-human mammals In the context of infections caused by S equi subsp. equi, the expression “non-human mammals” primarily refers to animals belonging to the family Equidae that consists of horses, donkeys and zebras and to hybrids thereof, such as mules and hinnies. In connection with infections caused by S. equi subsp. zooepidemicus, the expression “non-human mammals” in addition refers also to other mammals such as cows, pigs, dogs and cats.
- Fig. 1 shows IgG antibodies developed against FNZN in eight individual mice after intranasal inoculation with Streptococcus equi subsp. equi.
- Fig. 2 shows IgG antibodies developed against SFSCl in eight individual mice after intranasal inoculation with Streptococcus equi subsp. equi.
- Fig. 3 shows IgG antibodies developed against EAG4B in eight individual mice after intranasal inoculation with Streptococcus equi subsp. equi.
- Fig. 4 shows IgG antibodies developed in mice against FNZN after subcutaneous immunization with FNZN, SFSCl, and EAG4B. Results obtained for seven immunized mice and one non-immunized (T) mouse are shown.
- Fig. 5 shows IgG antibodies developed in mice against SFSCl after subcutaneous immunization with FNZN, SFSCl, and EAG4B. Results obtained for seven immunized animals and one non-immunized animal (T) are shown.
- Fig. 6 shows IgG antibodies developed in mice against EAG4B after subcutaneous immunization with FNZN, SFSCl, and EAG4B. Results obtained for seven immunized animals and one non-immunized animal (T) are shown.
- Fig. 7 shows IgG antibodies developed in mice after subcutaneous immunization with SEC 2.16. Results from five immunized and five non-immunized mice are shown. (Pre- immune sera gave no response, values closest to the base line with symbols overlapping each other).
- Fig. 9 shows nasal growth after subcutaneous immunization of mice with FNZN,
- SFSCl SFSCl
- Fig. 12 shows IgA antibodies against SFSCl in bronchoalveolar lavage (BAL) and nasal washes (NW) from mice nasally immunized with FNZN, SFSCl, and EAG4B. Results from six animals are shown.
- Fig. 13 shows weight loss of mice after intranasal immunization of mice with
- Fig. 14 shows IgG antibodies in immunized horses developed against EAG4B and FNZN.
- Fig. 15 shows the results from a comparison of serum antibody titers from horses with or without a history of strangles.
- Fig. 16 shows the presence of IgA antibodies in nasal washings from immunized horses.
- Fig. 17 shows antibody titers against EAG4B in horses immunized with EAG4B, FNZN, and SFSCl as a function of time
- Fig. 19 shows the results obtained for mice that were immunized with SEC2.16 alone
- the present invention is directed to an antigenic composition
- an antigenic composition comprising at least one antigen, wherein said at least one antigen comprises at least part of a protein of Streptococcus equi subsp. equi, and said at least part of said protein comprises at least one antigenic epitope or antigenic determinant of Streptococcus equi, and wherein said protein is comprised of a protein that is designated EAG and comprises an N-terminal amino acid sequence, which is shown below as SEQ. ID. NO: 1 and is designated EAG4B.
- said antigenic composition comprises at least one further antigen that comprises at least part of a fibronectin- binding protein of Streptococcus equi, said at least part of said protein comprising at least one antigenic epitope or antigenic determinant of Streptococcus equi, and wherein said protein is selected from the group consisting of FNZ (EMBL sequence data bank accession number X99995) comprising an amino acid sequence as shown in SEQ. ID. NO: 2 below:
- SFS comprising an amino acid sequence as shown in SEQ. ID. NO: 3 below: MRKTEGRFRTWKSKKQWLFAGAVNTSLLLGAALVFGGLLGSLGG
- the afore-mentioned antigenic compositions also comprise at least one further antigen that comprises at least part of an extracellular matrix -binding protein of Streptococcus equi and said at least part of said protein comprises an antigenic epitope or an antigenic determinant of Streptococcus equi and wherein said protein is comprised of a protein that is designated SEC and comprises an amino acid sequence as shown in SEQ. ID.
- the antigens of the present antigenic compositions may comprise the entire amino acid sequence of said protein or may comprise a fragment or analog thereof. Suitable fragments are ⁇ -terminal fragments of EAG and F ⁇ Z.
- An antigen derived from SFS may be comprised of a C-terminal part of SFS and an antigen derived from SEC may be comprised of a collagen-binding part of SEC.
- a preferred antigenic composition of the present invention contains all the afore-said antigens EAG, F ⁇ Z, SFS, and SEC.
- EAG antigens
- F ⁇ Z antigens
- SFS antigens
- SEC collagen-binding part of SEC
- the present antigens that are derived from proteins of Streptococcus equi may comprise the entire protein, a fragment of said protein or an analog of said protein.
- the present invention is not limited to the fragments of proteins that are specifically disclosed herein.
- a further embodiment of the present invention is concerned with a vaccine composition for protecting non-human mammals against infection of Streptococcus equi, which comprises an antigenic composition as disclosed above as immunizing component, and a pharmaceutically acceptable carrier.
- the present vaccine composition comprises an antigenic composition that contains all the afore-said antigens as immunizing component.
- one or more of these antigens are comprised of analogs of said proteins or fragments thereof, e.g. ⁇ -terminal or C-terminal fragments.
- the vaccine composition may comprise further components, such as an adjuvant.
- said adjuvant stimulates systemic or mucosal immunity. Such adjuvants are well known in the art.
- the vaccine composition is a vaccine that protects susceptible mammals, suitably horses, against strangles caused by Streptococcus equi subsp. equi.
- the vaccine composition of the present invention is provided in a physiologically administrable form. Suitably, it is administrable by subcutaneous or intranasal inoculation. Suitably, the vaccine composition of the present invention stimulates serum, mucosal and/or bronchial lavage antibody responses directed to Streptococcus equi antigens in mammals susceptible to Streptococcus equi, suitably horses.
- the present invention is also related to a method for producing an antigen to be used in an antigenic composition of the present invention, which method comprises
- step (c) culturing said host cell provided in step (b) under conditions required for expression of the product encoded by said DNA fragment; and (d) isolating the expressed product from the cultured host cell.
- said method further comprises a step (e) wherein the isolated product from step (d) is purified, e.g. by affinity chromatography or other chromatographic methods known in the art.
- a further embodiment of the present invention is concerned with a method for preparation of a vaccine of the present invention, which vaccine contains as immunizing component an antigenic composition as disclosed above, said method comprising mixing said antigenic composition and a pharmaceutically acceptable carrier.
- the present invention is also related to a method for the production of an antiserum, said method comprising administering an antigenic preparation of the present invention to an animal host to produce antibodies in said animal host and recovering antiserum containing said antibodies produced in said animal host.
- the present invention is concerned with a method of prophylactic or therapeutic treatment of S. equi infection in non-human mammals, suitably horses, comprising administering to said mammal an immunologically effective amount of a vaccine or an antiserum of the present invention.
- a suitable embodiment of the present invention is concerned with a method for protecting horses against Streptococcus equi infection, which comprises inoculating a horse subcutaneously or intranasally or both subcutaneously and intranasally with a vaccine of the present invention to induce an immune response against Streptococcus equi in said horse.
- a vaccine of the present invention to induce an immune response against Streptococcus equi in said horse.
- an immune response in the form of IgG and IgA antibodies in the nasopharyngeal mucus is thereby induced in said horse.
- the present invention describes the composition of a vaccine comprising one or several antigen components which have been prepared according to the present method using E. coli as host cells.
- the source of these antigens might also be the native bacteria, if methods are developed for expression and purification thereof.
- the antigens of the present invention can also be produced according to methods that are based on fusion strategies where various parts of the respective antigen are recombined resulting in a fusion protein consisting of parts from different antigens.
- This fusion strategy could also be suitable for introducing immune reactive part(s), e.g. T-cell epitopes or attenuated toxins (or parts thereof), thereby introducing other features suitable for optimizing the antigen presentation or localization.
- OZAG15 5'-TCA GCC ATG GCT CTA GAT GCT ACA ACG GTG TT-3'
- HSA human serum albumin
- the culture was harvested and the pellet was washed once in 50 ml PBS-D before it was resuspended in 40 ml of 20 mM Na phosphate, pH 7.0 (binding buffer).
- the resuspension was divided into two tubes and 10 mg lysozyme were added to each tube. After 2 hrs. of incubation at 37°C, the tubes were frozen at -20°C over night.
- the lysate was sonicated to fragmentize the DNA, centrifuged and the supernatant was filtered through a 0.45 ⁇ m filter.
- the column was washed with 30 ml binding buffer before the sample (corresponding to 1 liter of the over night culture) was applied onto the column. Thereafter, the column was washed with 50 ml binding buffer and the A 80 value was confirmed to be below 0.010. Bound protein was eluted in 0.1 M glycine-HCl, pH 3.0. The first 4.5 ml were not collected while the next 10 ml were collected as 1 ml fractions, which were neutralized by addition of 100 ⁇ l 1 M Tris-buffer, pH 8.0. Then, the column was regenerated by addition of binding buffer and stored at + 4°C in the presence of sodium azide.
- the A 280 value was determined and the fractions containing protein, normally fractions 1 to 5 or 6 were pooled and dialyzed 3 times against 4 liters of PBS-D. Thereafter, the protein was concentrated by extracting water from the dialysis tubing with PEG 30 000. From an over night culture of 2 liters, this procedure yielded 5-6 mg of an N-terminal fraction of the EAG protein, designated EAG4B and comprising the amino acid sequence recited above as SEQ. ID. NO: 1. In this sequence, the first amino acid presented in bold originates from the vector.
- nucleotide sequence of the fragment encoding EAG4B where the coding sequence starts from nucleotide 38(A) and ends at nucleotide 577(C) is shown below (SEQ. ID. NO: 7).
- the SFS protein from S. equi subsp. equi has previously been described by Lindmark and Guss (1999) (Ref. 12) and in WO 00/37496.
- the GeneBank accession number for the nucleotide sequence of the sfs gene is AF 136451.
- a C-terminal fragment of this protein was produced as follows: The 3 ' end of the sfs gene was PCR amplified using the Taq DNA polymerase (Amersham) and chromosomal DNA from S equi strain 1866 as template and the synthetic oligonucleotides
- OSFS25 5'-GGTCCCATGGCAACTCCGAATTTAGAAGGA-3' (SEQ. ID. NO: 8) and OSFS23: 5 ' -CAGACTCGAGGTCGGGATTGTAAGAATAG-3 ' (SEQ. ID. NO: 9) as primers.
- the PCR procedure was performed in 100 ⁇ l under standard conditions as regards buffer, template and primer concentration. The PCR cycles were performed under the following conditions: 1 min. of denaturation at 94°C, 30 sec. of annealing at 40°C, and 2 min. of extension at 72°C, which were repeated as 25 cycles. After amplification, the PCR product was purified using phenol extractions, chloroform extractions and EtOH precipitation. The purified DNA was cleaved with the restriction enzymes Nc ⁇ l and Xhol after which the D ⁇ A was purified as described above.
- the D ⁇ A obtained above was ligated into the plasmid vector pTYB4 [(New England Biolabs, Beverly, MA, USA (NEB Inc.)], which previously had been digested with the same restriction enzymes and treated with alkaline phosphatase. After ligation (using the ReadyToGo ligation kit, Amersham), the DNA sample was electrotransformed into the E. coli strain ER2566 and spread on LAA-plates (Luria Bertani agar plates supplemented with ampicillin, final cone. 50 ⁇ g/ml). After incubation over night at 37°C, clones harboring plasmids with inserts were isolated and the presence of the correct insert was verified by DNA sequencing. One of the clones thereby obtained, called SFSCl, was chosen for production of the C-terminal part of SFS.
- the vector used is a part of an E. coli expression and purification system called IMPACT 1 T7 (NEB Inc.). Briefly, following the manufacturer's instructions, the clone SFSCl was grown at 37 °C in Luria Bertani growth medium supplemented with ampicillin (final cone. 50 ⁇ g/ml). At an optical density (OD 6 oo ) of ⁇ 0.6, the growth medium was supplemented with IPTG (final cone. 0.4 mM) and the growth temperature was shifted to 20°C.
- OD 6 oo optical density
- the cells were harvested and resuspended in a buffer [20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 0.1 mM EDTA, and 0.1 % Triton X100], lysed by freezing and thawing, and after centrifugation, the supernatant was sterile filtered and applied to a chitin column.
- a buffer [20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 0.1 mM EDTA, and 0.1 % Triton X100]
- the column was extensively washed using the same buffer as above and was subsequently treated with cleavage buffer [20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 0.1 mM EDTA, and 30 mM dithiothreitol (DTT)].
- cleavage buffer [20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 0.1 mM EDTA, and 30 mM dithiothreitol (DTT)].
- the reducing conditions in the cleavage buffer induce an intein-mediated self-cleavage that releases the SFS part from the column while the intein-chitin-binding part remains bound.
- the eluted sample containing the product SFSCl was dialysed against phosphate-buffered saline [PBS; 137 mM NaCl, 2.7 mM KCI, 10 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 (pH 7.4)] and concentrated.
- PBS phosphate-buffered saline
- the amount of protein obtained was determined and the quality checked using SDS-PAGE.
- the purified protein has an amino acid sequence as recited below as SEQ. ID. NO: 10 except that the amino acid residues in bold are residues that correspond to the amino acid residues encoded by the pTYP4 vector, while remaining amino acid residues originate from the SFS protein.
- the EMBL accession number for the nucleotide sequences of the fnz gene is X99995.
- a similar truncated protein called FNE is also expressed by strains of S. equi subsp. equi [Lindmark et al (2001), Ref. 14].
- the GeneBank accession number for the nucleotide sequence of the fne gene is AF360373.
- pT2fhzN a clone called pT2fhzN encoding the N-terminal part of FNZ has previously been described by Lindmark et al 2001 (Ref. 14). Briefly, the clone pT2fhzN was constructed as follows using PCR amplification with the forward primer OFNZ1: 5'-ACCATGGCTAGCGCAGAGCAGCTTTATTATGGGT-3 ' (SEQ. ID. NO: 11), and the reverse primer
- OFNZ2 5'- ATACCCGGGATATCCTTCGGTACTACCATAGT-3 ' (SEQ. ID. NO: 12).
- Chromosomal DNA from subsp. zooepidemicus strain ZN was used as the template and the 5 ' end of the fnz gene was amplified.
- the PCR fragment obtained was cleaved with restriction endonucleases Nhel and Smal, followed by ligation into the corresponding restriction endonuclease sites in the expression vector pTYB2 ( ⁇ EB).
- ⁇ EB restriction endonuclease sites in the expression vector pTYB2
- the ligated D ⁇ A was electrotransformed into E. coli strain ER2566. Plasmids harboring inserts were isolated from transformants and verified by D ⁇ A sequencing.
- FNZN N-terminal part of FNZ
- the amino acid sequence of FNZN comprises then amino acid residues 32-337 of the amino acid sequence of the protein FNZ recited above as SEQ. ID. NO: 2.
- the corresponding amino acid sequence of FNZN is shown below as SEQ. ID. NO: 13.
- amino acids shown in bold originate from the protein FNZ in S. equi subspecies zooepidemicus, while those shown in normal type are derived from the expression vector construct.
- amino acids shown in bold originate from the protein FNZ in S. equi subspecies zooepidemicus, while those shown in normal type are derived from the expression vector construct.
- amino acids shown in bold originate from the protein FNZ in S. equi subspecies zooepidemicus, while those shown in normal type are derived from the expression vector construct.
- SEQ. ID. NO: 13 the first three and the last amino acid residues originate from the vector.
- the genome of S. equi is accessible (www.sanger.ac.uk) for computer analysis.
- By using earlier published sequences of virulence factors or potential virulence factors from pathogenic streptococci and staphylococci it is possible to screen the genome of S. equi for the presence of similar genes.
- protein SEC This protein, hereafter termed protein SEC (SEQ. ID. NO: 4), encodes an N-terminal signal sequence (amino acid sequence 1-26) followed by a region, which displays collagen-binding.
- the C-terminal part of protein SEC contains all typical features of cell surface proteins from streptococci, like putative wall anchoring and membrane spanning regions, as well as a motif corresponding to the LPDTG motif (SEQ. ID. NO: 14) of the protein SEC.
- the first construct encoding the major part of protein SEC was made as follows.
- OSEC3:3: 5'-CCGCTCGAGCTTGTAGCTTGGGTTAAGGGTGT -3' (SEQ. ID. NO: 17) were used to PCR-amplify a DNA-fragment corresponding to a sequence from amino acid no. 27 to amino acid no. 615 in protein SEC (SEQ. ID. NO: 4) using S. equi subspecies equi 1866 chromosomal DNA as a template.
- the second construct encoding the N-terminal part of protein SEC was made as follows.
- the primers OSECl:5 and 5 OSEC2:3: 5 ' -CCGCTCGAGAAAGCTGGTATAGCGACTGCCAT-3' (SEQ. ID. NO: 18) were used to PCR-amplify a DNA-fragment corresponding to a sequence from amino acid no. 27 to amino acid no. 328 in protein SEC (SEQ. ID. NO: 4) using S. equi subspecies equi 1866 chromosomal DNA as a template.
- step 1 95°C, 1 min
- step 2 95°C, 30 sec
- step 3 46°C, 15 sec
- step 4 72°C, 2 min; repeated as 25 cycles from step 2 to step 4.
- the respective PCR-products were purified and digested with restriction endonucleases Ncol and Xhol and ligated into the pTYB4-vector ( ⁇ EB) digested previously
- E. coli clones expressing collagen-binding were identified by colony screening using 125 I-labeled collagen (collagen S, type I obtained from Boeringher Mannheim). Several clones of both types of constructions expressing collagen-binding were identified and further characterized. One of these clones called pSEC 2.16 harboring the PCR-
- SEQ. ID. NO: 19 Insert of pSEC2.16
- the amino acid sequence of the recombinant collagen-binding protein SEC2.16 encoded by the insert of pSEC2.16 is shown below as SEQ. ID. NO: 20.
- the amino acids shown in bold represent amino acids originating from the vector. 5
- SEQ. ID. NO: 20 Protein SEC2.16
- SEQ. ID. NO. 21 15 corresponding nucleotide sequence is shown below as SEQ. ID. NO. 21. In this nucleotide sequence, the nucleotides shown in bold represent nucleotides originating from the vector. SEQ. ID. NO. 21 : Insert of pSECl.18
- the amino acid sequence of the recombinant collagen-binding protein SEC1.18 encoded by the insert of pSEC1.18 is shown below as SEQ. ED. NO: 22.
- the amino acids shown in bold represent amino acids originating from the vector.
- SEQ. ID. NO: 22 Protein SEC1.18.
- IMPACT-system ⁇ EB
- protein SEC 1.18 and protein SEC2.16 were analysed by SDS-PAGE using the Phast-System (Amersham Pharmacia) and 8-25% gradient gels under reducing conditions
- the purified proteins SEC 1.18 and SEC 1.16 were also analysed for their ability to bind to collagen.
- the proteins were run on an SDS-PAGE 8-25% gel (Amersham Pharmacia) under reducing conditions. After the electrophoresis was completed, the proteins were transferred (by diffusion) to a nitro-cellulose membrane. The membrane was blocked in a solution (PBS-T) containing PBS supplemented with TWEE ⁇ 20 (final concentration 0.5%)
- S. equi The genome of S. equi is accessible (www.sanger.ac.uk) for computer analysis.
- protein SEC it is possible to further screen the genome of S. equi for genes encoding earlier published sequences of virulence factors or potential virulence factors from pathogenic streptococci and staphylococci.
- Use of the soft ware program BLAST resulted in the identification in S.
- Example 5 Preparation of protein SclC and protein SCLC1
- the amino acid sequence of Streptpcoccus pyogenes protein SclB was used to screen the genome of S. equi (www.sanger.ac.uk) using the software program BLAST. As a result of this screening, an open reading frame was identified, which encodes a protein called SclC, which is similar to SclB.
- the protein SclC comprises an amino acid sequence as shown as SEQ. ID. NO: 23 below.
- SEQ. ID. NO: 23 1 MTNKTKRTGLVRKYGACSAAIALAALASLGAGKAVKAD QPAALKYPEPRDYFLHTREGDVIYDEDIKRYFEDLEAY LTARLGGIDKKVEEAAQKPGIPGPTGPQGPKGDKGDPG APGERGPAGPKGDTGEAGPRGEQGPAGQAGERGPKGD PGAPGPKGEKGDTGAVGPKGEKGDTGATGPKGDKGER GEKGEQGQRGEKGEQGQRGEKGEQKPKGDQGKDTKP SAPKAPEKAPAPKAPKASEQSSNPKAPAPKSAPSKSAA PTGQKAALPATGEINHPFFTLAALSVIASVGVLTLKGK KD 302
- the nucleotide sequence of the gene sclC encoding protein SclC is shown below as SEQ. ID. NO: 24.
- OSCL2:5: 5'- CATGCCATGGACCAGCCAGCAGCACTAAAATAT-3' (SEQ. ID. NO: 25) and OSCL3:3: 5'- CCGCTCGAGGGCTGCTTTTTGACCTGTTGGT-3 ' (SEQ. ID. NO: 26) were used to PCR-amplify a DNA-fragment corresponding to amino acid 38 to amino acid 269 in protein SclC using S equi subspecies equi 1866 chromosomal DNA as a template.
- PCR amplification was performed using ReadyToGoTM PCR beads (Amersham Pharmacia Biotech Inc) and the PCR apparatus MiniCyclerTM (MJ Research, Inc, MA, USA) using a program of step 1: 95°C, 1 min; step 2: 95°C 30 sec; step 3: 50°C 15 se ; step 4: 72°C, 1 min; repeated as 24 cycles from step 2 to step 4.
- the respective PCR-products were purified and digested with restriction endonucleases Ncol and Xhol and ligated into the pTYB4-vector ( ⁇ EB) previously digested with the same enzymes.
- ⁇ EB pTYB4-vector
- One ⁇ l of the respective ligation mixture was transformed into E. coli ER2566. E. coli clones harboring the sclc fragment were identified by D ⁇ A sequencing of the inserted fragments.
- protein SCLC1 comprises the amino acid sequence shown below as SEQ. ID. NO: 27.
- Example 6 The purified protein SCLCl was then used to immunize mice and rabbits and was also used to screen convalescence sera from horses for measurements of antibody titers against SCLCl. This is illustrated in Example 6 below.
- Example 6 Immunization of rabbits using protein SCLCl and Western blot Protein SCLCl was used to immunize a rabbit. This work was done at the company Agrisera (Nannas, Sweden). Using an ELISA format, where the SCLCl protein was immobilized in microtiter wells, the immune serum obtained was analysed for presence of antibodies against SCLCl. The results showed that the immune sera could be diluted > 30 000 and still react with the SCLCl protein (as compared to the pre-immune serum, which did not contain any significant level of antibodies against SCLCl).
- the SCLCl protein was also run on an SDS-PAGE gel using the Phast-System (Amersham Pharmacia) and 8-25% gradient gel under reducing conditions. After the electrophoresis had been completed, the SCLCl protein was diffusion blotted to a nitrocellulose-membrane. After blocking, the membrane was divided and immune serum (dilution 1:10 000 in PBS-0.05%Tween 20) and pre-immune serum, respectively, were added and incubated for two hours at room temp. After washing in PBS-0.05%Tween 20, secondary antibodies (anti rabbit IgG, horseradish-labelled and developed in goat, Sigma) were used to detect rabbit antibodies directed against SCLCl. The result showed that the immune serum detected the immobilized SCLCl protein efficiently, while no detection was seen using the pre-immune serum.
- Bacterial strain and growth Streptococcus equi subsp. equi was isolated from a horse with strangles. After one passage in a mouse (inoculated intranasally and reisolated from a submandibular gland), the bacteria were stored at -80°C. To prepare an inoculum, stored bacteria were first grown on a blood agar plate, subcultured overnight at 37°C in Todd Hewitt medium containing 1% (w/v) yeast extract. Six ml of this culture were taken into 50 ml of Todd Hewitt /Yeast extract medium (BBL, Becton Dickinson) containing 10% (v/v) equine, i.e. horse, serum (heat inactivated) and incubated at 37°C for 4 hrs. Bacteria grown this way were used in animal challenge experiments.
- Todd Hewitt /Yeast extract medium BBL, Becton Dickinson
- mice and experimental design NMRI outbred female mice (Mollegard, Denmark) having a body weight of about 20 g, were individually marked, and kept in groups of four in each cage. Daily, they were weighed and nose impressions onto a BG plate (sheep blood and gentian violet) were taken to quantify bacterial growth. After incubation at 37°C in 5 % CO 2 for 24 hrs, the amount of haemolytic colonies was determined according to a scale of 0-3. A score of 3 means confluent growth of Streptococcus subsp equi on the whole plate and a score of 0 indicates 0-4 colonies.
- BAL Bronchoalveolar lavage
- NW nasal wash
- Example 7 Immune response in mice subjected to infection with Streptococcus subsp. equi
- mice samples Serum dilutions from the mice samples were applied. After washing, rabbit antibodies against mice IgG conjugated with horse radish peroxidase (Dako) were added. To develop the color reaction, OPD tablets (Dako) were added according to instructions from the manufacturer.
- Dako horse radish peroxidase
- Example 8 Immune response in mice immunized with FNZN, SFSCl, and EAG4B
- mice were immunized subcutaneously on days 0, 7, 14, and 21. Twelve mice were given antigens (FNZN, SFSCl, and EAG4B) and adjuvant and twelve mice were given only adjutvant. The adjuvant used was EtxB provided by Dr Tim R. Hirst, University of Bristol. Each animal was given 12 ⁇ g of each antigen and 36 ⁇ g of EtxB at each occasion. On day 28, the mice were sacrificed and blood samples were taken. ELISA tests were performed as described above. All mice developed IgG antibodies against FNZN, SFSCl, and EAG4B. Samples from seven mice and a negative control are shown in Figures 4, 5, and 6 for FNZN, SFSCl, and EAG4B, respectively.
- Example 10 Subcutaneous immunization with FNZN, SFSCl, and EAG4B followed by challenge with Streptococcus equi subsp equi
- mice were subcutaneously immunized on days 0, 7, 14, and 21. Twelve mice were given antigens (FNZN, SFSCl, and EAG4B) and the adjuvant EtxB and twelve mice were given only adjuvant. Each animal was given 12 ⁇ g of each antigen and 36 ⁇ g of EtxB at each occasion. On day 28, the mice were infected with Streptococcus equi subsp. equi. Ten ⁇ l of bacteria containing lxlO 6 CFU were given intranasally to anaesthetized mice. Animals that lost more than 15% of weight were killed. Mice that had survived or had lost less than 15% of weight are shown in Figure 8.
- Weight loss versus time is shown in Figure 10; on days 2, 3, 4, 5, and 8, the p-values were 0.04, 0.017, 0.005, 0.003, and 0.002, respectively.
- Nasal growth versus time is shown in Figure 11 ; on days 4 to 8, the p-value was O.001.
- IgA antibody titers in BAL/NW and sera were determined by ELISA. Briefly, microtiter plates (Costar) were coated with 10 ⁇ g/ml of FNZN, SFSCl, and EAG4B. Serial dilutions of BAL/NWs were added to the wells. After washing, goat anti mouse IgA conjugated with horse radish peroxidase (Dako) was added.
- the animals were subjected to challenge infection with subsp. equi.
- the number of animals that died or lost more than 15% weight were different in the two groups; five vaccinated mice and 8 non-vaccinated died ( Figure 18). This is not a statistically significant difference but is a tendency implying an effect of SEC2.16. It is likely that it would give a synergistic effect together with any or all of the other antigens mentioned above. Growth of subsp. equi in the noses was also studied.
- FNZ, SFS and EAG were selected.
- Four groups (A-D) of horses with three horses in each group were immunized as follows: A) EAG4B, FNZN and SFSCl with EtxB as adjuvant, and given both intranasally and subcutaneously; B) As in group A but given only intranasally; C) as in A but without EtxB as adjuvant; and D) Only EtxB, and no antigens, given both intranasally and subcutaneously. Each dose consisted of 35 ⁇ g of each antigen and 100 ⁇ g of EtxB in a volume of 2 ml for intranasal and/or subcutaneous immunization. Immunizations were given on days 0, 14, 28 and 42.
- Serum samples were taken and analysed as follows: Microtiter wells (Costar) were coated overnight with 100 ⁇ l FNZN, SFSCl, or EAG4B, at 10 ⁇ g per ml overnight in phosphate buffered saline (PBS). The plates were then blocked with 2% (w/v) bovine serum albumin (BSA) for 1 hour at 37°C. After washing, horse sera were added to wells at a 20-fold dilution, followed by 2-fold serial dilutions. The plates were washed after 1 hour of incubation at 37°C. After washing, detection of antibody binding was performed with antibodies, diluted lOOOx, against horse IgG, raised in rabbit and conjugated with HRP (Sigma Chemical Co). Development of a colorimetric reaction was achieved with OPD tablets (Dako, Denmark). Absorbance was determined spectrophotometrically at 492 nm.
- Example 13 Determination in ELISA of antibody titers from horses with or without a history of previous strangles
- Microtiter wells (Costar) were coated overnight with lOO ⁇ l
- FNZN, SFSCl, EAG4B, SEC2.16 or SCLCl at 10 ⁇ g per ml overnight in phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the plates were then blocked with 2% (w/v) BSA for 1 hour at 37°C. After washing, horse sera were added to wells at a 20-fold dilution, followed by 2-fold serial dilutions. The plates were washed after 1 hour incubation at 37°C. Detection of antibody binding was performed after washing, with antibodies, diluted lOOOx, against horse IgG, raised in rabbits and conjugated with HRP (Sigma Chemical Co). Development of a colorimetric reaction was achieved with OPD tablets (Dako, Denmark).
- Example 14 Determination of IgA antibody titers from, immunized horses
- Horses were divided into four groups (A-D) and were immunized as described in Example 12.
- Antigen-specific IgA in nasal wash samples from immunized horses were determined by an indirect ELISA.
- Monoclonal antibody K129-3E7 (2 ⁇ g/ml) against equine IgA was used to detect bound IgA in the samples followed by use of a goat anti -mouse immunoglobulin HRP conjugate (2 ⁇ g/ml). Coating concentrations of antigens were 4 ⁇ g/ml. Background values (from no-antigen plates) were subtracted. All samples were analyzed in triplicate.
- Antigen-specific IgA ELISA data is expressed relative to the total IgA ELISA data in order to correct for nasal secretion dilution during the nasal wash procedure.
- Total IgA in nasal wash samples was determined by a capture ELISA using two different monoclonal antibodies specific to equine IgA. One was used to coat wells and the other was biotinylated and was detected with the use of a streptavidin-HRP conjugate. The concentrations of monoclonal antibody and streptavidin-HRP were optimized so that none of these was limiting in the assay. Samples were analysed in triplicate. In Figure 16, the Absorbance values obtained for IgA against FNZN and EAG4B are shown.
- Example 15 Determination of kinetics for development of IgG in immunized horses.
- Horses were immunized as described in Example 12. On days 0, 14, 28 and 42, samples were taken on these days and on day 56 as well and analyzed as described elsewhere. The horses were immunized with EAG4B, FNZN and SFSCl with EtxB, by both intranasal and subcutaneous route.
- mice vaccinated with EAG4B with EtxB as adjuvant kept loosing weight and on day 14 weight loss in this group was 12.5%.
- the difference in weight loss on day 14 implies that supplying EAG4B together with other antigens, such as SFSCl and/or FNZN improves protection. However, the difference is not significant due to small sample size. (No data shown)
- Protein F a fibonectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes. Proc. Natl. Acad. Sci. USA 89:6172-6176.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03751693A EP1560594B1 (en) | 2002-10-11 | 2003-10-10 | Antigenic compositions for immunization of non-human mammals against streptococcus equi |
AT03751693T ATE471156T1 (en) | 2002-10-11 | 2003-10-10 | ANTIGEN COMPOSITIONS FOR IMMUNIZING NON-HUMAN MAMMALS AGAINST STREPTOCOCCUS EQUI |
DE60333027T DE60333027D1 (en) | 2002-10-11 | 2003-10-10 | ANTIGENIC COMPOSITIONS FOR IMMUNIZING NON-MENTAL MAMMALS AGAINST STREPTOCOCCUS EQUI |
AU2003269765A AU2003269765B2 (en) | 2002-10-11 | 2003-10-10 | Immunization of non-human mammals against streptococcus equi |
CA2501621A CA2501621C (en) | 2002-10-11 | 2003-10-10 | Immunization of non-human mammals against streptococcus equi |
DK03751693.7T DK1560594T3 (en) | 2002-10-11 | 2003-10-10 | Antigenic Compositions for Immunization of Non-Human Mammals against Streptococcus equi |
NZ539255A NZ539255A (en) | 2002-10-11 | 2003-10-10 | Antigenic compositions and use thereof for immunisation of non-human mammals such as horses against Streptococcus equi |
US10/530,879 US8404245B2 (en) | 2002-10-11 | 2003-10-10 | Immunization of non-human mammals against Streptococcus equi |
HK06101817.3A HK1085646A1 (en) | 2002-10-11 | 2006-02-10 | Antigenic compositions for immunization of non-human mammals against streptococcus equi |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41766002P | 2002-10-11 | 2002-10-11 | |
US60/417,660 | 2002-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004032957A1 true WO2004032957A1 (en) | 2004-04-22 |
Family
ID=32094057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2003/001587 WO2004032957A1 (en) | 2002-10-11 | 2003-10-10 | Immunization of non-human mammals against streptococcus equi |
Country Status (10)
Country | Link |
---|---|
US (1) | US8404245B2 (en) |
EP (1) | EP1560594B1 (en) |
AT (1) | ATE471156T1 (en) |
AU (1) | AU2003269765B2 (en) |
CA (1) | CA2501621C (en) |
DE (1) | DE60333027D1 (en) |
DK (1) | DK1560594T3 (en) |
HK (1) | HK1085646A1 (en) |
NZ (1) | NZ539255A (en) |
WO (1) | WO2004032957A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2019687A2 (en) * | 2006-03-29 | 2009-02-04 | Merial Limited | Vaccine against streptococci |
WO2009075646A1 (en) | 2007-12-13 | 2009-06-18 | Bengt Guss | Improved immunizing composition |
WO2011149419A1 (en) | 2010-05-26 | 2011-12-01 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
EP2498812A1 (en) * | 2009-11-13 | 2012-09-19 | Bengt Guss | Immunizing composition for reducing streptococcal infections |
US8329194B2 (en) | 2003-07-01 | 2012-12-11 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
US20150044208A1 (en) * | 2011-09-23 | 2015-02-12 | Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa | Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics |
US9023366B2 (en) | 2003-07-01 | 2015-05-05 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114437235B (en) * | 2022-01-04 | 2024-02-09 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | Recombinant fusion protein of streptococcus equi subspecies 8 proteins, and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000436A1 (en) | 1985-07-12 | 1987-01-29 | Cornell Research Foundation, Inc. | The protection of equines against streptococcus equi |
WO1992007002A1 (en) | 1990-10-22 | 1992-04-30 | Alfa-Laval Agri International Aktiebolag | A collagen binding protein as well as its preparation |
WO1995007296A1 (en) | 1993-09-06 | 1995-03-16 | Bengt Guss | Method and means for producing plasmaproteinase inhibitor-binding proteins |
US5583014A (en) | 1990-07-03 | 1996-12-10 | Bayer Corporation | Preparation and use of enzyme-detergent extracted Streptococcus zoopidemicus vaccine |
WO1998001561A1 (en) | 1996-07-03 | 1998-01-15 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | SUBUNIT VACCINE FOR $i(STREPTOCOCCUS EQUI) |
WO2000037496A1 (en) | 1998-12-22 | 2000-06-29 | Bengt Guss | Novel fibronectin-binding protein |
-
2003
- 2003-10-10 CA CA2501621A patent/CA2501621C/en not_active Expired - Fee Related
- 2003-10-10 US US10/530,879 patent/US8404245B2/en active Active
- 2003-10-10 WO PCT/SE2003/001587 patent/WO2004032957A1/en not_active Application Discontinuation
- 2003-10-10 DE DE60333027T patent/DE60333027D1/en not_active Expired - Lifetime
- 2003-10-10 AT AT03751693T patent/ATE471156T1/en not_active IP Right Cessation
- 2003-10-10 DK DK03751693.7T patent/DK1560594T3/en active
- 2003-10-10 NZ NZ539255A patent/NZ539255A/en not_active IP Right Cessation
- 2003-10-10 AU AU2003269765A patent/AU2003269765B2/en not_active Ceased
- 2003-10-10 EP EP03751693A patent/EP1560594B1/en not_active Expired - Lifetime
-
2006
- 2006-02-10 HK HK06101817.3A patent/HK1085646A1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000436A1 (en) | 1985-07-12 | 1987-01-29 | Cornell Research Foundation, Inc. | The protection of equines against streptococcus equi |
US5583014A (en) | 1990-07-03 | 1996-12-10 | Bayer Corporation | Preparation and use of enzyme-detergent extracted Streptococcus zoopidemicus vaccine |
WO1992007002A1 (en) | 1990-10-22 | 1992-04-30 | Alfa-Laval Agri International Aktiebolag | A collagen binding protein as well as its preparation |
WO1995007296A1 (en) | 1993-09-06 | 1995-03-16 | Bengt Guss | Method and means for producing plasmaproteinase inhibitor-binding proteins |
WO1998001561A1 (en) | 1996-07-03 | 1998-01-15 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | SUBUNIT VACCINE FOR $i(STREPTOCOCCUS EQUI) |
WO2000037496A1 (en) | 1998-12-22 | 2000-06-29 | Bengt Guss | Novel fibronectin-binding protein |
Non-Patent Citations (31)
Title |
---|
ANTON MAYR ET AL.: "Handbuch der Shutzimpfungen in der Tiermedizin.3.3.4", VERLAG PAUL PAREY, pages: 196 - 200 |
B. MOREIN; KARIN LOVGREN BENGTSSON, IMMUNOLOGY AND CELLBIOLOGY, vol. 76, 1998, pages 295 - 299 |
BARNHAM, M.; A. LJUNGGREN; M. MCINTYRE.: "Human infection with Streptococcus zooepidemicus (Lancefield group C): three case reports", EPIDEM. INF., vol. 98, 1987, pages 183 - 190 |
COURTNEY, H. S. ET AL.: "Cloning, sequencing and expression of a fibronectinlfibrinogen-binding protein from group A streptococci", INFECT. IMMUN., vol. 62, 1994, pages 3937 - 3946 |
CUE, D. ET AL.: "Streptococcus pyogenes serotype M 1 encodes multiple pathways for entry into human epithelial cells", INFECT. IMMUN, vol. 66, 1998, pages 4593 - 4601 |
ELSON, C.O.; M.T. DERTZBAUGH.: "Nucosal immunology", ACADEMIC PRESS, pages: 817 - 838 |
ENGVALL, E.; E. RUOSLAHTI; J. M. MILLER.: "Affinity offibronectin to collagen of different genetic types and to fibronogen", J. EXP. MED., vol. 147, 1978, pages 1584 - 1595 |
GALÁN, J.E.; J. F. TIMONEY.: "Immunologic and genetic comparison of Streptococcus equi isolates from the United States and Europe", J. CLIN. MICROBIOL., vol. 26, 1988, pages 1142 - 1146 |
HANSKI, E.; M.G. CAPARON.: "Protein F, a fibonectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes", PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 6172 - 6176 |
HANSKI, E.; P.A. HORWITZ; M.G. CAPARON: "Expression of protein F, the Fibronectin-binding protein of Streptococcus pyogenes JRS4, in heterologous streptococcal and enterococcal strains promotes their adherence to respiratory epithelial cells", INFECT. IMMUN., vol. 60, 1992, pages 5119 - 5125 |
HYNES, T. O.: "Fibronectins", 1990, SPRINGER VERLAG, article "Fibronectins" |
JACOBSSON, K. ET AL.: "Shot-gun phage display mapping of two streptococcal cell-surface proteins", MICROBIOL RES., vol. 152, 1997, pages 1 - 8 |
JADOUN, J. ET AL.: "Protein F required for efficient entry of Streptococcus pyogenes into epithelial cells", J. INFECT. DIS., vol. 178, 1998, pages 147 - 158 |
JONSSON, H.; LINDMARK, H.; GUSS. B.: "A protein G related cell surface protein in Streptococcus zooepidemicus", INFECT IMMUN, vol. 63, 1995, pages 2968 - 2975 |
LANNERGARD JONAS ET AL.: "CNE, a collagen-binding protein of streptococcus equi", FEMS MICROBIOLOGY LETTERS, vol. 222, 2003, pages 69 - 74, XP002971919 * |
LANNERGÅRD, J.; FRYKBERG, L.; GUSS B.: "CNE, a collagen-binding protein of Streptrococcus equi", FEMS MICROBIOL. LETT., vol. 222, 2003, pages 69 - 74 |
LINDMARK HANS ET AL.: "Comparison of the fibronectin-binding protein FNE from streptococcus equi subspecies equi with FNZ from S. equi subspecies zooepidemicus reveals a major and conserved difference", INFECTION AND IMMUNITY, vol. 69, no. 5, May 2001 (2001-05-01), pages 3159 - 3163, XP002971923 * |
LINDMARK HANS ET AL.: "Pulsed-field gel electrophoresis and distribution of the genes zag and fnz in isolates of streptococcus equi", RESEARCH IN VETERINARY SCIENCE, vol. 66, 1999, pages 93 - 99, XP002971922 * |
LINDMARK HANS ET AL.: "SFS, a novel fibronectin-binding protein from streptococcus equi, inhibits the binding between fibronectin and collagen", INFECTION AND IMMUNITY, vol. 67, no. 5, May 1999 (1999-05-01), pages 2383 - 2388, XP000906770 * |
LINDMARK HANS ET AL.: "The NH2-terminal half of protein FNZ binds fibronectin and is secreted in S. equi subsp. equi but not in subsp. zooepidemicus", SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES, 1999, UPPSALA, pages 1 - 13, XP002971921 * |
LINDMARK HANS: "Characterization of adhesive extracellular proteins from streptococcus equi", DOCTORAL THESIS SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES, 1999, UPPSALA, pages 7 - 49, XP002971920 * |
LINDMARK, H. ET AL.: "Fibronectin-binding protein of Streptococcus equi subspecies zooepidemicus", INFECT IMMUN, vol. 64, 1996, pages 3993 - 3999 |
LINDMARK, H. ET AL.: "Pulsed-field gel electrophoresis and distribution of the genes zag and fnz in isolates of Streptococcus equi", RES VET SCI., vol. 66, 1999, pages 93 - 99 |
LINDMARK, H.: "Characterization of adhesive extracellular proteins from Streptococcus equi", DOCTORAL THESIS, vol. 139, 1999 |
LINDMARK, H.; GUSS, B.: "SFS, a novel fibronectin-binding protein from Streptococcus equi, inhibits the binding between fibronectin and collagen", INFECT. IMMUN., vol. 67, 1999, pages 2383 - 2388 |
LINDMARK, H.; NILSSON, M.; GUSS, B., COMPARISON OF THE FIBRONECTIN-BINDING PROTEIN FNE FROM STREPTOCOCCUS EQUI SUBSPECIES EQUI WITH FNZ FROM S. EQUI SUBSPECIES ZOOEPIDEMICUS REVEALS A MAJOR AND CONSERVED DIFFERENCE, vol. 69, 2001, pages 3159 - 3163 |
MOLINRI, G. ET AL.: "The fibronectin-binding protein of Streptococcus pyogenes SfbI, is involved in the internalization of group A streptococci by epithelial cells", INFECT. IMMUN., vol. 65, 1997, pages 1357 - 1363 |
OGRA ET AL., CLINICAL MICROBIOLOGY REVIEWS, April 2002 (2002-04-01), pages 430 - 445 |
PATTI, J. M. ET AL.: "Molecular characterization and expression of a gene encoding a Staphylococcus aureus collagen adhesin", J BIOL. CHEM., vol. 267, 1992, pages 4766 - 4772 |
SCHNEEWIND, 0.; FOWLER, A.; FAULL, K.F.: "Structure of the cell wall anchor of surface proteins in Staphylococcus aureus", SCIENCE, vol. 268, 1995, pages 103 - 106 |
WINNER ET AL., INFECT. IMMUN., vol. 59, 1991, pages 997 - 982 |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8329194B2 (en) | 2003-07-01 | 2012-12-11 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
US9023366B2 (en) | 2003-07-01 | 2015-05-05 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
EP3167900A1 (en) | 2006-03-29 | 2017-05-17 | Merial Limited | Vaccine against streptococci |
EP3167900B1 (en) | 2006-03-29 | 2018-11-21 | Merial Limited | Vaccine against streptococci |
EP2019687A4 (en) * | 2006-03-29 | 2012-02-15 | Merial Ltd | Vaccine against streptococci |
JP2009531464A (en) * | 2006-03-29 | 2009-09-03 | メリアル リミテッド | Vaccines against streptococci |
EP2759307A3 (en) * | 2006-03-29 | 2014-12-10 | Merial Limited | Vaccine against Streptococci |
EP2019687A2 (en) * | 2006-03-29 | 2009-02-04 | Merial Limited | Vaccine against streptococci |
EP2759307A2 (en) | 2006-03-29 | 2014-07-30 | Merial Limited | Vaccine against Streptococci |
EP2227249A1 (en) * | 2007-12-13 | 2010-09-15 | Intervacc AB | Improved immunizing composition |
EP2227249A4 (en) * | 2007-12-13 | 2011-08-31 | Intervacc Ab | Improved immunizing composition |
US9987342B2 (en) | 2007-12-13 | 2018-06-05 | Intervacc Ab | Immunizing composition |
WO2009075646A1 (en) | 2007-12-13 | 2009-06-18 | Bengt Guss | Improved immunizing composition |
EP2498812A4 (en) * | 2009-11-13 | 2013-05-22 | Bengt Guss | Immunizing composition for reducing streptococcal infections |
EP2498812A1 (en) * | 2009-11-13 | 2012-09-19 | Bengt Guss | Immunizing composition for reducing streptococcal infections |
EP2590994A4 (en) * | 2010-05-26 | 2014-04-30 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
AU2011258898B2 (en) * | 2010-05-26 | 2015-05-07 | Intervacc Ab | Vaccine against Streptococcal infections based on recombinant proteins |
US9333252B2 (en) | 2010-05-26 | 2016-05-10 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
EP3135684A1 (en) | 2010-05-26 | 2017-03-01 | Intervacc AB | Vaccine against streptococcal infections based on recombinant proteins |
EP2590994A1 (en) * | 2010-05-26 | 2013-05-15 | Intervacc AB | Vaccine against streptococcal infections based on recombinant proteins |
US9795664B2 (en) | 2010-05-26 | 2017-10-24 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
WO2011149419A1 (en) | 2010-05-26 | 2011-12-01 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
US20150044208A1 (en) * | 2011-09-23 | 2015-02-12 | Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa | Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics |
Also Published As
Publication number | Publication date |
---|---|
US8404245B2 (en) | 2013-03-26 |
AU2003269765A1 (en) | 2004-05-04 |
EP1560594A1 (en) | 2005-08-10 |
NZ539255A (en) | 2007-12-21 |
CA2501621A1 (en) | 2004-04-22 |
HK1085646A1 (en) | 2006-09-01 |
ATE471156T1 (en) | 2010-07-15 |
EP1560594B1 (en) | 2010-06-16 |
CA2501621C (en) | 2012-01-24 |
DK1560594T3 (en) | 2010-10-04 |
AU2003269765B2 (en) | 2009-08-06 |
DE60333027D1 (en) | 2010-07-29 |
US20060140980A1 (en) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9795664B2 (en) | Vaccine against streptococcal infections based on recombinant proteins | |
US9987342B2 (en) | Immunizing composition | |
JP2012504660A5 (en) | ||
AU2012207089B2 (en) | Vaccines and compositions against Streptococcus pneumoniae | |
US8404245B2 (en) | Immunization of non-human mammals against Streptococcus equi | |
JPH08505282A (en) | Combined vaccine against group B streptococcus | |
US20120225079A1 (en) | Immunizing composition for reducing streptococcal infections | |
US8501197B2 (en) | Compositions and methods for stimulating immune response against Moraxella catarrhalis | |
AU2013205101A1 (en) | Improved immunizing composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2501621 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 539255 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003269765 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003751693 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003751693 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006140980 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10530879 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10530879 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |